The use of certain drugs, influencing the appearance of

dyspeptic syndrome
Koppandi Oana, Asist. Univ. Drd. Koppandi Alexandra, Asist.
Univ. Drd. Borza Corina, Asist. Univ. Drd. Daraban Adriana Maria
The study is based on an analysis of data collected from a total of 30
patients, diagnosed with dyspepsia or dyspepsia episodes in history. The
method used was a complex questionnaire for these patients at the routine
consultation, in the family doctor's office. The results show, that most of the
patients that use treatments for other diseases, answered that they use
NSAIDs (23.3%), which is a major influence in the apparition of dyspeptic
syndrome. The studied group also has a number of patients (10%) treated
with iron for anemia.
Treatment of anemia with iron, it takes long periods of time,
depending on the severity of the deficit. During this treatment, digestive
symptoms may occur due to excess of Fe: nausea, vomiting, stomach burns,
as an expression of the erosion of the gastric mucosa. The same symptoms
can be correlated with the use of dietary supplements that contain K. Nonsteroidal anti-inflammatory drugs (ex. aspirin, ibuprofen and its derivatives)
create lesions on the mucous membrane of the stomach by inhibiting the
enzymes responsible for its protection. Other drugs with adverse effects on
gastric mucosa: steroids, chemotherapy.

New lines of pharmacological treatment in type 2 diabetes

in adults
Koppandi Oana, Asist. Univ. Drd. Koppandi Alexandra, Asist.
Univ. Dr. Rusu Andreea, Marian Mihaela, Hornea Paula
Diabetes is a significant condition due to the current increase in the
number of patients, but also in terms of the increased costs for treating and
diagnosing this disorder. This condition has a significant social impact
because of the high frequency and severity of complications and comorbidity, enhancing the therapeutic difficulties.
Glinides, although not sulfonylureas, they have similar actions. As in
the case of sulfonylureas, the effect depends on the presence of functional
pancreatic cells. Thus, it initiates a series of reactions that as a result, the
release of insulin, the action is fast and short termed.

Sitagliptin and saxagliptin are inhibitors of dipeptidyl peptidase-IV,

used for treatment in type 2 diabetes. There are currently developing other
agents in this class.
Agents that mimic the actions of incretins (exenatidum, liraglutidum)
are also a new line of therapy for type 2 diabetes. Incretins, glucosedependent insulinotropic polypeptide (GIP) and glucagon like peptide 1 (GLP1) are intestinal hormones, secreted postprandial. They stimulate the release
of insulin by the pancreas, when the serum concentration of glucose is
increased. Their trophic effect on pancreatic cells, inhibits the release of
glucagon, and the evacuation of the stomach and stimulates the satiety
center.